Reported about 1 month ago
Catalent reported fourth-quarter revenues of $1.3 billion, surpassing analyst estimates of $1.22 billion. The growth was bolstered by its biologics segment, which drew significant interest ahead of a $16.5 billion acquisition by Novo Holdings, set to close by the year's end. This deal, driven by the demand for Novo Nordisk's Wegovy, involves the sale of three key manufacturing sites to Novo Nordisk for $11 billion. Catalent also achieved an adjusted profit of 65 cents per share, exceeding predictions.
Source: YAHOO